LXX.CN - Lexaria Bioscience Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
2.27
-0.01 (-0.44%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.28
Open2.31
Bid2.27 x 0
Ask2.30 x 0
Day's Range2.18 - 2.40
52 Week Range0.44 - 3.23
Volume101,205
Avg. Volume111,472
Market Cap164.611M
Beta (3Y Monthly)4.56
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIREyesterday

    Lexaria Bioscience Receives Two New Granted Patents

    KELOWNA, BC / ACCESSWIRE / October 18, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has been granted two new US patents. Lexaria now has six granted patents in the US and four granted patents in Australia. All ten of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".

  • ACCESSWIRE9 days ago

    Lexaria Bioscience Creates and Brands Subsidiary Companies

    KELOWNA, BC / ACCESSWIRE / October 10, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has completed the creation of four wholly-owned subsidiary companies. This new corporate structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. The subsidiaries are each empowered with Lexaria's patented DehydraTECHTM technology.

  • GlobeNewswire11 days ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Among World’s Biggest Holders of Cannabis Patents

    NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP). Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective.

  • GlobeNewswire14 days ago

    CannabisNewsWire Announces IP and Intangible Assets, Particularly in Pharma Sector, Increasingly Dominate Global Business Landscape

    NEW YORK, Oct. 05, 2018 -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • GlobeNewswire16 days ago

    The Race to Speed Up the Effects of Cannabis -- CFN Media

    SEATTLE, Oct. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits. The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states.

  • ACCESSWIRE21 days ago

    Lexaria Files New Patent Application for Delivery of Tobacco-Derived Products

    KELOWNA, BC / ACCESSWIRE / September 28, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the filing of a new strategic patent application. The new provisional patent application is entitled "Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof". This application represents Lexaria's tenth patent family and expands the applicability of the already-patented DehydraTECHTM technological process to impart benefits to tobacco leaves that may be utilized to deliver compounds that may or may not include nicotine.

  • ACCESSWIRElast month

    Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance

    KELOWNA, BC / ACCESSWIRE / September 7, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company"or "Lexaria"), a drug delivery platform innovator, announces strategic additions to its patent portfolio. Three new Australian patents were granted to Lexaria by the Australian Patent Office, bringing the Company's worldwide patent portfolio to eight issued patents: four each in the US and Australia.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results

    Lexaria's technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria's formulation was 4x faster at reaching its peak level in brain tissue than the non-enhanced control formulation. KELOWNA, BC / ACCESSWIRE / August 30, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces further results from its recently completed second-generation study in 40 rats (two groups of 20 each) in addition to those released on August 7, 2018.

  • GlobeNewswire2 months ago

    NetworkNewsWire Announces Publication on Viable and Effective Alternatives for Nicotine Delivery

    NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience (CSE:LXX) (LXRP), a client of NNW focused on developing and out-licensing its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids and nicotine. Lexaria recently announced the results of its second in vivo study of 2018 evaluating the use of DehydraTECH as a nicotine delivery system. Speed of absorption is one of the most important issues for non-inhalation forms of nicotine delivery, given the rapidity with which smoking gets the drug into the body, so this is a strong sign for the potential of DehydraTECH as a smoking alternative.

  • GlobeNewswire2 months ago

    CFN Exclusive Interview: Lexarias DehydraTECH Could Transform the $680 Billion Tobacco Industry -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of a CEO video interview and article discussing Lexaria Bioscience Corp. (CSE:LXX) (CN) (CNSX:LXX) (LXRP). In recent in-vivo animal studies, the company demonstrated that its delivery technology achieved nearly double the delivery than non tech-enhanced edible forms of nicotine, as well as significantly improve nicotine absorption across all subsequent time points — making it a compelling nicotine replacement option. While the negative side-effects of smoking have reduced cigarette volumes, many existing smokers don’t have a viable alternative that delivers nicotine quickly enough into the bloodstream.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing: Delivery Measured Within Minutes

    This study represents Lexaria's second in vivo nicotine study, building on the previous nicotine breakthrough study announced April 17, 2018. CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has successfully delivered nicotine in an edible form into blood plasma just minutes after dosing in an animal in vivo study. Speed of onset is a key attribute for oral drug administration, and it is of particular importance for the consideration of non-inhalation nicotine delivery formats.

  • GlobeNewswire3 months ago

    Lexaria’s DehydraTECH Triples Bioavailability of CBD in Human Trial -- CFN Media

    The company has spent the past several years focused on improving the bioavailability of cannabinoids, including CBD. Its DehydraTECH™ drug delivery platform has demonstrated significant improvements in bioavailability over conventional delivery methods — and its latest human clinical study confirmed these findings.

  • ACCESSWIRE3 months ago

    Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

    KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report ...

  • ACCESSWIRE3 months ago

    Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

    "Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval. The Definitive Agreement is the conclusion of the process begun following the announcement of the non-binding letter of intent in April 2018. Terms of the Definitive Agreement were not disclosed.

  • ACCESSWIRE4 months ago

    Lexaria Announces 2018 AGM Results and Corporate Update

    KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special ...

  • CNW Group4 months ago

    Horizons ETFs Completes Rebalances of its Marijuana-focused ETFs

    TORONTO , June 29, 2018 /CNW/ - Horizons ETFs Management (Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences ...

  • ACCESSWIRE4 months ago

    Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / June 29, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. In recent laboratory testing, Lexaria's breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECHTM than concentration-matched controls lacking DehydraTECHTM enhancements.

  • ACCESSWIRE5 months ago

    Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries

    KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (''IP'') related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (''NSAIDs''), phosphodiesterase (''PDE5'') inhibitors and other active pharmaceutical ingredients. This proposed structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each.

  • ACCESSWIRE5 months ago

    Lexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement

    KELOWNA, B.C. / ACCESSWIRE / May 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant transactions. Lexaria announces it has received US$63,000 from the exercise of warrants previously granted. The Company has received for exercise a total of 450,000 warrants with an exercise price of US$0.14, previously granted.

  • ACCESSWIRE5 months ago

    Lexaria Bioscience Corp. Receives New Granted Patents

    KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th. Once granted, Lexaria will have 4 granted patents in the US and 4 granted patents in Australia. All eight of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof", and significantly strengthen Lexaria's intellectual property ("IP") claims in the US and Australia.